Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Glaxo Bid Undervalues Human Genome Sciences, Sunday Times Says

Don't Miss Out —
Follow us on:

April 29 (Bloomberg) -- GlaxoSmithKline Plc’s $2.6 billion offer for Human Genome Sciences Inc. “completely undervalues” the company according to a major shareholder, the Sunday Times reported.

Mark Evans from Taube Hodson Stonex Partners LLP, a fund manager that owns 5.6 percent of the U.S. drugs maker, termed the bid “unacceptable,” the London-based newspaper said.

Human Genome rejected Glaxo’s $13-a-share cash offer on April 19.

To contact the reporter on this story: Lucy Meakin in London at

To contact the editor responsible for this story: Daniel Tilles at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.